Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q4 FY22 results · Jan–Mar 2022
Cohance Lifesciences reported revenue from operations of ₹363.85 crore (up 40.4% from Q4 FY21) and net profit of ₹91.67 crore (up 10.3% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 363.85 | 259.16 | +40.4% | 391.59 | −7.1% |
| Other income | 16.87 | 3.30 | +411.5% | 64.69 | −73.9% |
| Total income | 380.72 | 262.46 | +45.1% | 456.27 | −16.6% |
| Profit before tax | 161.28 | 86.80 | +85.8% | 239.46 | −32.6% |
| Net profit for the period | 91.67 | 83.12 | +10.3% | 160.07 | −42.7% |
| EPS, basic (₹) | 3.60 | 3.27 | +10.1% | 6.29 | −42.8% |
| Net margin (%) | 25.2 | 32.1 | 40.9 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 363.85 | 259.16 | +40.4% | 391.59 | −7.1% |
| Other income | 134.40 | 3.30 | 41x | 9.27 | 14x |
| Total income | 498.24 | 262.46 | +89.8% | 400.86 | +24.3% |
| Profit before tax | 279.36 | 86.81 | +221.8% | 184.05 | +51.8% |
| Net profit for the period | 224.46 | 64.45 | +248.3% | 137.00 | +63.8% |
| EPS, basic (₹) | 8.82 | 2.53 | +248.6% | 5.38 | +63.9% |
| Net margin (%) | 61.7 | 24.9 | 35.0 |
Consolidated
- Filed with BSE
- 10 May 2022, 16:42 IST
- Board meeting
- 09 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 May 2022, 16:42 IST
- Board meeting
- 09 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE